Key Takeaways Shares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality.Stryker will acquire Inari in an all-cash deal for $80 per share,

Stryker has entered a definitive agreement to acquire complete issued and outstanding shares of Inari Medical’s common stock for $80 per share in cash, which equates to a total equity value of nearly $4.9bn. Inari is poised to enhance Stryker's footprint in the peripheral vascular sector, particularly in the venous thromboembolism (VTE) market.

Medical device maker Stryker said it has reached a deal to acquire Inari Medical for $80 per share in cash, representing an approximate value of $4.9 billion.

Inari makes mechanical thrombectomy solutions designed to treat peripheral vascular diseases. Stryker said the deal would be complementary to its neurovascular business.

Stryker said its planned acquisition of Inari Medical would strengthen its position in the peripheral vascular market.

Stryker announces agreement to acquire Inari Medical for $4.9 billion, resulting in a 21% jump in Inari's shares.

A deal for Inari, which has a market value of nearly $3 billion, would bolster Stryker’s efforts to build out its offerings to treat a condition called venous thromboembolism

Stryker Corporation SYK recently inked a definitive agreement to acquire all the issued and outstanding shares of common stock of Inari Medical, Inc. NARI for $80 per share in cash, representing a total fully diluted equity value of approximately $4.

Inari Medical's stock surged 6% amid reports of advanced acquisition talks with Stryker, potentially closing a deal this week.